Practice Location
- OncoCare Cancer Centre
Mount Elizabeth Novena Specialist Centre - Oncocare Cancer Centre (Gleneagles)
Gleneagles Medical Centre - Oncocare Cancer Centre (Mount Alvernia)
Medical Centre D, Mount Alvernia Hospital - Oncocare Cancer Centre (Orchard)
Mount Elizabeth Medical Centre
Accredited Hospitals:
- Gleneagles Hospital Singapore
- Mount Alvernia Hospital Singapore
- Mount Elizabeth Hospital Singapore
- Mount Elizabeth Novena Hospital Singapore
Educational Qualifications
- MBBS – University of Delhi, India
Languages
English, Hindi, Punjabi
His interests include thoracic and head and neck oncology, urologic oncology, malignant hematology including Hodgkin’s and non-Hodgkin’s lymphomas, and gastrointestinal oncology including hepatocellular carcinoma (liver cancer). As a senior specialist in cancer medicine, he has a wide experience seeing cancer patients from various countries such as India, United Arab Emirates, USA, European countries as well as Asian nations including Bangladesh, Vietnam, Myanmar, Cambodia, Malaysia and Indonesia with help of interpreters.
He has published with his colleagues experience in treating lung cancer patients with malignant pleural effusion whereby the role for talc pleurodesis was investigated. These patients with adenocarcinoma of the lung were treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs) such as Erlotinib (Tarceva) and Gefitinib (Iressa). His publication also relates to liver toxicity of such medications in non-small cell lung cancer. He has also analyzed with his collaborators, first line treatment of advanced kidney cancer (clear cell carcinoma) using bevacizumab with interferon, sunitinib, pazopanib and interferon.
He was actively involved as principal and co-investigator in several industry sponsored as well as investigator-initiated trials in different tumor types. He has a special interest in use of immunotherapy to treat cancers and has been a principal investigator for several clinical trials using immunotherapy agents in multiple tumor types. He is one of the authors in a clinical trial involving multiple regional cancer centers in liver cancer (hepatocellular cancer). This trial published in the reputable journal, Lancet, involves the early use of nivolumab, a programmed cell death protein-1 (PD-1) immune checkpoint inhibitor, in patients with advanced hepatocellular carcinoma with or without chronic viral hepatitis (CheckMate 040 trial).
Recommend this doctor to a friend:
